Table 1.

Patient characteristics, diagnosis and histological variant of Multicentric Castleman’s disease (MCD)

Patient nr./age at MCD Dg		HIV Dg (mo/y)	MCD Dg (mo/y)	Histological variant of MCD	KS (y)	HIV VL at MCD Dg (copies/ml)	CD4 cells at and nadir before MCD Dg (cells/μl)	HHV8 VL at MCD Dg (copies/µg DNA)	cART at MCD Dg	First-line therapy	MCD relapse (y)	Outcome (last follow-up)
1	40	01/2008	10/2008	Plasma cell	NA	104	204/114	61.000	2 PI + INI	Rituximab	2009, 2010	In remission (12/2020)
2	63	03/2002	08/2010	Hyaline vascular	2002, 2011 (relapse)	< 40	234/90	1.020	2NRTI + INI + PI	Rituximab	NA	Lost to follow-up (04/2011)
3	36	07/2011	07/2011	Plasma cell	2011	2.05 2.676	96/96	218.000	None	Rituximab	NA	Deceased (2012)
4	28	12/2012	01/2013	No histological confirmation	2013	< 40	4/4	466.000	None	Rituximab	NA	In remission (12/2020)
5	54	05/1996	10/2015	Plasma cell	2005, 2007	255	527/109	193.000	2NRTI + INI	Rituximab, tocilizumab, splenectomy	2019	Deceased (2019)
6	67	01/2005	05/2017	Plasma cell	NA	70	41/41	49.500	2NRTI + INI	Tocilizumab, rituximab	2019	In remission (11/2020)
7	71	11/2015	08/2017	Plasma cell	2015	< 20	133/54	46.500	2NRTI + PI	Rituximab		In remission (11/2020)
8	44	07/2003	12/2017	Plasma cell	2019	102	10/10	288.000	2NRTI + PI	Rituximab, tocilizumab, splenectomy	2019, 2020	Deceased (2020)
9	39	08/2016	02/2018	Plasma cell	NA	184	379/159	111.000	2NRTI + INI	Rituximab	NA	In remission (12/2020)

Virologic and immunologic parameters at MCD diagnosis as well as therapies and outcome

Dg Diagnosis; m male; KS Kaposi Sarcoma; VL viral load; mo month; y year; cART combination antiretroviral therapy; NRTI nucleoside reverse transcriptase inhibitor; INI integrase inhibitor; PI protease inhibitor; NA not applicable